Product image of Medikinet (Methylphenidate Hydrochloride) supplied by GNH India

Medikinet

Active Ingredient:
Methylphenidate Hydrochloride
Origin:
EU

Medikinet (Methylphenidate Hydrochloride)

Methylphenidate Hydrochloride, the active ingredient in Medikinet, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH India supplies Medikinet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medice Arzneimittel Pütter Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Medikinet, a central nervous system stimulant, is indicated for conditions involving dopamine and norepinephrine dysregulation.

  • Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity in children, adolescents, and adults.
  • Narcolepsy: decreases excessive daytime sleepiness and reduces cataplexy episodes.
  • Behavioral difficulties associated with ADHD: helps improve academic performance and social functioning in patients with attention deficits.

How It Works

  • Methylphenidate Hydrochloride blocks the reuptake of dopamine and norepinephrine by inhibiting their respective transporters in the central nervous system. This increases synaptic concentrations of these neurotransmitters, enhancing neuronal signaling in pathways that regulate attention, wakefulness, and impulse control.

Side Effects

Methylphenidate Hydrochloride may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Insomnia: difficulty falling or staying asleep.
  • Appetite loss: reduced hunger leading to weight loss.
  • Headache: mild to moderate cranial pain.
  • Gastrointestinal upset: nausea, stomach pain or abdominal discomfort.
  • Increased heart rate: mild tachycardia or palpitations.
  • Mood changes: irritability or anxiety.

Serious or Rare Side Effects

  • Cardiovascular events: hypertension, arrhythmia, or myocardial infarction.
  • Psychiatric symptoms: psychosis, severe agitation, or mania.
  • Growth suppression: prolonged use may affect height development in children.
  • Allergic reactions: rash, urticaria, or anaphylaxis.
  • Seizures: rare occurrence of convulsive episodes.

Precautions & Warnings

Before prescribing Medikinet, clinicians should assess patient history and monitor for specific risks.

  • Cardiovascular assessment: evaluate blood pressure and heart rate prior to initiation and periodically thereafter.
  • Psychiatric evaluation: screen for history of psychosis, bipolar disorder, or severe anxiety.
  • Growth monitoring: track height and weight in pediatric patients during long‑term therapy.
  • Drug abuse potential: consider risk of misuse in patients with substance‑use disorders.
  • Concomitant medications: review for agents that may increase blood pressure or interact with stimulant metabolism.
  • Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Methylphenidate Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome.
  • Sympathomimetic agents (e.g., decongestants): may cause excessive cardiovascular stimulation.

Moderate Interactions (Monitor Closely)

  • Antihypertensive drugs: possible reduction in blood‑pressure‑lowering effect.
  • CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase methylphenidate plasma levels.
  • Acid‑reducing agents: can affect absorption, requiring clinical observation.

Frequently Asked Questions

Medikinet contains methylphenidate hydrochloride and is prescribed for attention deficit hyperactivity disorder (ADHD) and narcolepsy. In ADHD it helps improve focus, reduce hyperactivity, and control impulsive behavior, while in narcolepsy it lessens daytime sleepiness and cataplexy.

Methylphenidate hydrochloride blocks the reuptake of dopamine and norepinephrine at neuronal synapses, raising their levels in the brain. The increased neurotransmitter activity enhances attention pathways and promotes wakefulness, which underlies its therapeutic effects in ADHD and narcolepsy.

The dose of Medikinet is individualized by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and response to therapy. Dosage adjustments are made during follow‑up visits to achieve optimal benefit while minimizing adverse effects.

Safety data for methylphenidate use in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks to the fetus or infant. If treatment is essential, close monitoring is recommended, and breastfeeding decisions should be made in consultation with a healthcare professional.

To request Medikinet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Medikinet (methylphenidate) and other stimulants such as amphetamine‑based products share a similar mechanism of increasing dopamine and norepinephrine. Differences lie in pharmacokinetic profiles, duration of action, and individual tolerability. Choice of therapy depends on patient response, side‑effect profile, and prescriber preference.

Medikinet should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture, heat, and direct sunlight to maintain stability throughout the shelf life.

Medikinet is taken orally, usually with a glass of water. It may be prescribed as a single daily dose or divided doses depending on the formulation and clinical judgment. Patients should follow the prescribing physician’s instructions regarding timing and whether to take it with or without food.

Serious risks include cardiovascular events such as hypertension, arrhythmia, or myocardial infarction, as well as psychiatric complications like psychosis, severe agitation, or mania. Rarely, growth suppression in children and seizure occurrence have been reported. Prompt medical attention is required if any of these symptoms arise.

Medikinet is contraindicated in individuals with known hypersensitivity to methylphenidate or any excipients, those taking monoamine oxidase inhibitors, and patients with severe cardiovascular disease, uncontrolled hypertension, or a history of psychosis. A thorough medical evaluation is essential before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methylphenidate Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT